Rosenberg L, Stephenson W P, Rao R S, Palmer J R, Strom B L, Shapiro S
Slone Epidemiology Unit, School of Public Health, Boston University School of Medicine, Brookline, MA 02146, USA.
Cancer Causes Control. 1998 Dec;9(6):611-4. doi: 10.1023/a:1008830431939.
Renal cell cancer has been associated with hypertension or with drugs to treat it in several studies. We assessed whether the association is explained by more frequent detection of early renal cell cancer among persons being treated for hypertension.
The data were collected in our Case-Control Surveillance Study, in which patients aged 20 to 69 years were interviewed in hospitals in Baltimore, Boston, New York, and Philadelphia during 1976-1996. We compared 134 incident cases of renal cell cancer who were being treated with drugs for hypertension to 193 untreated cases with respect to the route to diagnosis and the stage.
The relative risk estimate for having been diagnosed incidentally during a routine examination or workup for another condition, relative to having been diagnosed because of symptoms of renal cell cancer, was 1.3 (95 percent confidence interval, 0.7-2.5). The estimate for diagnosis at stage I or II relative to stage III or IV was 1.2 (0.7-2.1).
In Case-Control Surveillance Study data, the relative risk estimate for renal cancer among users of various classes of antihypertensive drugs is 1.8 or 1.9. The present results suggest that this association can, at most, be explained only partially by the selective diagnosis of renal cell cancer among persons being treated for hypertension.
多项研究表明肾细胞癌与高血压或治疗高血压的药物有关。我们评估了这种关联是否可由高血压患者中早期肾细胞癌的更频繁检测来解释。
数据收集于我们的病例对照监测研究,在1976年至1996年期间,对巴尔的摩、波士顿、纽约和费城医院中20至69岁的患者进行了访谈。我们比较了134例正在接受高血压药物治疗的肾细胞癌新发病例与193例未接受治疗的病例在诊断途径和分期方面的情况。
相对于因肾细胞癌症状而被诊断,在常规检查或因其他病症进行检查期间偶然被诊断的相对风险估计值为1.3(95%置信区间,0.7 - 2.5)。I期或II期诊断相对于III期或IV期的估计值为1.2(0.7 - 2.1)。
在病例对照监测研究数据中,各类抗高血压药物使用者患肾癌的相对风险估计值为1.8或1.9。目前的结果表明,这种关联最多只能部分地由高血压患者中肾细胞癌的选择性诊断来解释。